PUBLICATIONS
Decreased Opioid Utilization with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis
Retrospective Claims Analysis of Decreased Healthcare Visits with Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch
Topical Delivery Systems Effectively Transport Analgesics to Areas of Localized Pain via Direct Diffusion
Review of Multimodal Therapies for the Treatment of Neuropathic Pain: Clinical Implications
Impact of Adhesion on Patient Satisfaction, Medication Switching and Discontinuation With Lidocaine Topical Patches Based on FDA Adverse Event Reporting and Patient Surveys
Decreased Healthcare Resource Utilization With Lidocaine Topical System 1.8% Compared to Lidocaine 5% Patch: A Retrospective Claims Analysis
Pain Freedom With Celecoxib Oral Solution, Ubrogepant, and Rimegepant Through 4 Hours Postdose: Post Hoc Analysis in the Acute Treatment of Migraine
Detection and Adjustment for Participant Response Effects in a 2-Period, Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Oral Solution for the Acute Treatment of Migraine
65th Anual Scientific Meting of the American Headache Society, in Austin, TX.
View Article Online | Download ArticleResults from a Pivotal Phase 3, DB, R, Placebo-controlled, Multicenter Trial of SP-102, a Novel Dexamethasone Injectable Formulation, for the Treatment of Patients with Lumbosacral Radiculopathy (Sciatica)
Corporate Presentation
Safety of Epidural Steroid Injections for Lumbosacral Radicular Pain
A Randomized, Crossover, Pharmacokinetic and Adhesion Performance Study of a Lidocaine Topical System 1.8% During Physical Activity and Heat Treatment in Healthy Subjects
Biorelevant In Vitro Skin Permeation Testing and In Vivo Pharmacokinetic Characterization of Lidocaine from a Nonaqueous Drug-in-Matrix Topical System
AAPS PharmSciTech (2021) 22:215 DOI: 10.1208/s12249-021-02101-y
View Article Online | Download ArticleRepeat Epidural Injections of SP-102 (Dexamethasone Sodium Phosphate Injectable Gel) in Subjects with Lumbosacral Radiculopathy
Open-label adhesion performance studies of a new lidocaine topical system 1.8% versus lidocaine patches 5% and lidocaine medicated plaster 5% in healthy subjects.
Characteristics of Analgesic Patch Formulations.
A Randomized, Open-Label, Bioequivalence Study of Lidocaine Topical System 1.8% and Lidocaine Patch 5% in Healthy Subjects
A Randomized, Crossover, Adhesion Performance and Pharamcokinetic Study of a Lidocaine Topical System Under Conditions of Water Exposure in Healthy Subjects.
Utility of lidocaine as a topical analgesic and improvements in patch delivery systems.
Postgraduate Medicine, 132:1, 28-36, DOI: 10.1080/00325481.2019.1702296.
View Article Online | Download ArticleTreatment Patterns and Medication Use in Patients with Postherpetic Neuralgia
J Manag Care Spec Pharm. 2019 Dec;25(12):1387-1396. Epub 2019 Oct 7.
View Article Online | Download ArticleEmail Alert
